Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?

Author(s): Asterios Karagiannis, Dimitri P. Mikhailidis, Anna I. Kakafika, Konstantinos Tziomalos, Vasilios G. Athyros

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 2 , 2007

Become EABM
Become Reviewer
Call for Editor


The beneficial effect of antihypertensive treatment on the risk of major vascular events is well established. Several trials comparing older and newer drugs in the treatment of primary hypertension suggested that it is the blood pressure achieved, rather than choice of the drug that determines most of the primary outcomes. Beta-blockers have been widely used to treat hypertension and are still recommended as first-line drugs in guidelines. However, recent meta-analyses of trials (either placebo-controlled or using drug comparisons) involving atenolol (a popular beta-blocker), have cast doubt on the suitability of atenolol as a first-line antihypertensive drug. We consider the mechanisms which might be responsible for the inferiority of atenolol in preventing vascular morbidity and mortality in patients with primary hypertension. This knowledge may help design drugs that are not only more effective in achieving blood pressure targets but that also markedly decrease vascular events.

Keywords: Beta-blockers, atenolol, vascular, morbidity, mortality, Primary hypertension

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [229 - 239]
Pages: 11
DOI: 10.2174/138161207779313713
Price: $65

Article Metrics

PDF: 4